GLP-1 Receptor Agonist Side Effects and Safety Profile
GLP-1 receptor agonist thermoregulatory symptoms such as chills and hot flashes are important side effects to recognize. These symptoms reflect metabolic adaptations during therapy and can affect patient adherence. Understanding these effects helps…
GLP-1 Receptor Agonists: Vision Loss and ION Risks
Idiopathic optic neuropathy risk has been associated with GLP-1 receptor agonists, particularly semaglutide formulations. Recent pharmacovigilance data highlights vision loss concerns requiring baseline vision screening. Clinicians should counsel…
GLP-1 Receptor Agonist Guidance: What the WHO Data Shows
The WHO guidance on GLP-1 receptor agonists highlights their role in obesity management and global treatment standards. This guidance impacts coverage policies and prescribing practices. Clinicians should understand these recommendations to optimize…
Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine in Schedule I
The DEA drug scheduling updates include placing 3-methoxyphencyclidine in Schedule I due to its high abuse potential. This synthetic phencyclidine analog lacks accepted medical use. Understanding these updates helps clinicians anticipate regulatory…
